{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=79", "query": { "condition": "Lymphoid", "page": 79 }, "page_size": 10 }, "pagination": { "page": 79, "page_size": 10, "total_count": 3083, "total_pages": 309, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=80&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=78&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T09:53:49.843Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00772486", "title": "A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "ISF35", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memgen, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2008-09", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00772486" }, { "nct_id": "NCT00779883", "title": "A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "ISF35", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memgen, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2006-06", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2008-10-24", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00779883" }, { "nct_id": "NCT02384954", "title": "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Altor BioScience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2015-04-17", "completion_date": "2020-12-13", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 4, "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Columbus, Ohio + 1 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02384954" }, { "nct_id": "NCT00002756", "title": "Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "asparaginase", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "1 Year", "sex": "ALL", "summary": "Up to 1 Year" }, "enrollment_count": 221, "start_date": "1996-06", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2014-02-14", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 128, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 114 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002756" }, { "nct_id": "NCT07356245", "title": "Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Lymphoma", "Graft Versus Host Disease", "Lymphoma, T-Cell", "Peripheral T Cell Lymphoma", "T-cell Prolymphocytic Leukemia", "Cutaneous T Cell Lymphoma", "Adult T-cell Leukemia/Lymphoma", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Positron emission tomography-computed tomography", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2026-02-12", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 2, "location_summary": "Columbus, Ohio • Houston, Texas", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07356245" }, { "nct_id": "NCT00344786", "title": "Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "CNF2024 (BIIB021)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2006-02", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2009-06-05", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 3, "location_summary": "San Diego, California • New York, New York • Houston, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00344786" }, { "nct_id": "NCT00642031", "title": "Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies", "Leukemia" ], "interventions": [ { "name": "Triciribine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prescient Therapeutics, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20, "start_date": "2006-08", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2016-08-09", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 2, "location_summary": "Tampa, Florida • Houston, Texas", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642031" }, { "nct_id": "NCT00002970", "title": "506U78 in Treating Patients With Refractory Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Lymphoblastic Lymphoma", "T-cell Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "nelarabine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 148, "start_date": "1997-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002970" }, { "nct_id": "NCT01139970", "title": "Veliparib and Temozolomide in Treating Patients With Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A", "Adult Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA", "Adult B Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Adult T Acute Lymphoblastic Leukemia", "Alkylating Agent-Related Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-06-04", "completion_date": "2018-12-01", "has_results": false, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 3, "location_summary": "Chicago, Illinois • Baltimore, Maryland", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01139970" }, { "nct_id": "NCT06651970", "title": "Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Lymphocytic Leukaemia", "Moderate to Severe Cardiac Impairment" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Investigator's choice of treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 60, "start_date": "2025-02-04", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-13T09:53:49.843Z", "location_count": 3, "location_summary": "Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06651970" } ] }